Maribel Kamp
Family · San Antonio, TXNPI 1790385037
Payments from drug & device makers
Across 292 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$1K
- AstraZeneca$1K
- Bayer$775
- Amgen$648
- Calliditas Therapeutics US Inc.$466
- Travere Therapeutics, Inc.$429
- plus $4K from 26 others
What the payments were for
- Food & beverage$7,828100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 63 | $1,025 |
| AstraZeneca(2 entities) | 28 | $1,008 |
| Bayer | 27 | $775 |
| Amgen(2 entities) | 29 | $648 |
| Calliditas Therapeutics US Inc. | 19 | $466 |
| Travere Therapeutics, Inc. | 14 | $429 |
| Akebia Therapeutics Inc | 14 | $371 |
| Otsuka America Pharmaceutical, Inc. | 11 | $342 |
| Aurinia Pharma U.S., Inc. | 7 | $297 |
| Novo Nordisk | 9 | $266 |
| Ardelyx, Inc. | 13 | $250 |
| Vifor Pharma, Inc. | 11 | $247 |
| Lilly USA, LLC | 11 | $213 |
| Si-bone, Inc. | 1 | $133 |
| Novartis | 6 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $127 |
| Corcept Therapeutics | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $120 |
| Abiomed | 1 | $120 |
| Philips North America LLC | 1 | $109 |
| Abbott | 1 | $108 |
| GSK | 5 | $106 |
| Stemline Therapeutics Inc. | 1 | $98 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| AbbVie | 3 | $54 |
| Veloxis Pharmaceuticals, Inc. | 2 | $53 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| Surmodics, Inc. | 2 | $41 |
| Polynovo North America LLC | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Outset Medical Inc | 1 | $20 |
| Hydrofera LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$468
- Rayaldee$370
- Kerendia$368
- Filspari$125
- Korlym$125
- KRYSTEXXA$124
- NURTEC ODT$120
- Impella$120
- GATTEX$114
- (5044) MCOT$109
- FreeStyle Libre 2$108
- TARPEYO$106
How this compares
$7,852 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 50 | $80,959 |
| FarxigaDapagliflozin Propanediol | 51 | $44,756 |
| JanuviaSitagliptin Phosphate | 15 | $24,438 |
| KerendiaFinerenone | 23 | $18,919 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $16,843 |
| MounjaroTirzepatide | 11 | $11,640 |
| Nebivolol Hcl | 14 | $811 |
| Bumetanide | 14 | $619 |
| Furosemide | 73 | $472 |
| Metoprolol Succinate | 12 | $360 |
| Olmesartan Medoxomil | 15 | $352 |
| Nifedipine ErNifedipine | 11 | $307 |
| Tamsulosin Hcl | 16 | $302 |
| Hydralazine Hcl | 29 | $279 |
| Lisinopril | 11 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $1,025 | $80,95950 claims |
| AstraZenecaFarxiga, Lokelma | $1,008 | $61,59965 claims |
| BayerKerendia | $775 | $18,91923 claims |
| Lilly USA, LLCMounjaro | $213 | $11,64011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.